VC warns AI drug abundance will worsen biopharma R&D productivity for 3-5 years
rbhar90 · x · 2026-11-01
LifeSciVC argues AI-driven molecular design will flood the industry with new drugs against known targets over the next 3-5 years, exacerbating crowding and dragging down aggregate R&D productivity before the long-term benefits arrive — drawing a parallel to the 2001 'Fruits of Genomics' report that correctly predicted target-abundance indigestion after the Human Genome Project.
More from AGI Musings
- Can LLMs turn surprising observations into research questions and discover physical laws? — rohanpaul_ai · 2026-11-01
- Gamers push back: 'We want MORE AI in gaming, not less' — petewoodbridge · 2026-11-01
- 'Don't recreate existing games': AI platform terms spark open-asset fears — TinfoilTricorn · 2026-11-01
- Altman prefers trillions of AIs checking each other; skeptics ask who owns them — VraserX · 2026-11-01
- RL Legend Szepesvári Defends Academia: Your Research Raises the Water Level — CsabaSzepesvari · 2026-11-01
- Sam Altman: Using latest AI tools feels like managing a factory inside a computer — haider1 · 2026-11-01